Production (Stage)
Adverum Biotechnologies, Inc.
ADVM
$2.21
-$0.02-0.90%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 0.00 | 1.00M | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 0.00 | 1.00M | -- | -- |
| Cost of Revenue | 28.75M | 24.10M | 20.44M | 17.10M | 15.41M |
| Gross Profit | -28.75M | -24.10M | -19.44M | -17.10M | -15.41M |
| SG&A Expenses | 19.47M | 38.12M | 9.78M | 3.79M | 13.79M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 48.22M | 62.22M | 30.22M | 20.88M | 29.20M |
| Operating Income | -48.22M | -62.22M | -29.22M | -20.88M | -29.20M |
| Income Before Tax | -47.02M | -60.53M | -27.13M | -18.48M | -27.15M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -47.02M | -60.53M | -27.13M | -18.48M | -27.15M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -47.02M | -60.53M | -27.13M | -18.48M | -27.15M |
| EBIT | -48.22M | -62.22M | -29.22M | -20.88M | -29.20M |
| EBITDA | -47.54M | -61.41M | -28.33M | -19.93M | -28.20M |
| EPS Basic | -2.25 | -2.90 | -1.30 | -0.89 | -1.65 |
| Normalized Basic EPS | -1.40 | -1.81 | -0.81 | -0.55 | -1.03 |
| EPS Diluted | -2.25 | -2.90 | -1.30 | -0.89 | -1.65 |
| Normalized Diluted EPS | -1.40 | -1.81 | -0.81 | -0.55 | -1.03 |
| Average Basic Shares Outstanding | 20.94M | 20.90M | 20.88M | 20.85M | 16.48M |
| Average Diluted Shares Outstanding | 20.94M | 20.90M | 20.88M | 20.85M | 16.48M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |